Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Acura settles patent suit with Sandoz, licenses nonexclusive rights to Aversion oxycodone generic

Executive Summary

In the US District Court for the District of Delaware, Acura Pharmaceuticals Inc. (abuse-resistant drug candidates) settled pending patent litigation with Novartis AG’s Sandoz Inc. surrounding the former’s Aversion formulation of oxycodone for acute and chronic moderate-to-severe pain.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies